首页> 外文OA文献 >Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab

【2h】

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab

机译：患者稳定的转换和停止模式均发芽的英夫利昔单抗，他们切换到英夫利昔单抗或留在发起者infliximab上

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Timothy Fitzgerald; Richard Melsheimer; Marie-Hélène Lafeuille; Patrick Lefebvre; Laura Morrison; Kimberly Woodruff; Iris Lin; Bruno Emond;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial [J] . Jorgensen Kristin K., Olsen Inge C., Goll Guro L., The Lancet . 2017,第10086期

机译：与发芽治疗的发起者英美昔单抗切换到生物仿制物CT-P13与发起者英夫利昔单抗（NOR-SWITCH）的治疗相比：52周，随机，双盲，非劣势试验
2. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial (vol 389, pg 2304, 2017) [J] . Jorgensen K. K., Olsen I. C., Goll G. L. The Lancet . 2017,第10086期

机译：从发起者infliximab转换为生物仿制物CT-P13与发起者incriximab（NOR-SWITCH）的维护治疗相比：52周，随机，双盲，非劣势试验（Vol 389，PG 2304,2017）
3. Comparing Patients Responding Well to Infliximab-Originator and Patients Switched to an Infliximab-Biosimilar. A Preliminary Analysis from the Rhumadata Clinical Database and Registry [J] . Choquette Denis, Bessette Louis, Haraoui Boulos, The Journal of rheumatology . 2019,第7期

机译：将患者与富集昔单抗的患者进行比较，患者切换到英夫利昔单抗。 rhumadata临床数据库和注册表的初步分析
4. INNOVATOR AND BIOSIMILAR INFLIXIMAB: COMPARABILITY ASSESSMENT OF THE HOST CELL PROTEINS AND PROTEIN HIGHER ORDER STRUCTURE [C] . Jing Fang, Catalin Doneanu, William R. Alley, ASMS Conference on Mass Spectrometry and Allied Topics . 2016

机译：创新者和生物纤维单纤维生素：宿主细胞蛋白和蛋白质高阶结构的可比性评估
5. A Cost-utility Analysis of Biosimilar Infliximab Compared to Reference Infliximab in Adult Switch Patients with Crohn's Disease: A Canadian Analysis [D] . Hughes, Avery. 2018

机译：生物纤维生素infiximab的成本实用性分析与成人交换患者参考incriximab患者克罗恩病患者：加拿大分析
6. Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab [O] . Timothy Fitzgerald, Richard Melsheimer, Marie-Hélène Lafeuille, 2021

机译：患者稳定的转换和停止模式均发芽的英夫利昔单抗他们切换到英夫利昔单抗或留在发起者infliximab上
7. POS0592 BIOSIMILAR INFLIXIMAB THERAPY IN RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS: A LONG-TERM FOLLOW-UP STUDY ON INFLIXIMAB-NAÏVE PATIENTS AND PATIENTS SWITCHED FROM THE ORIGINATOR TO THE BIOSIMILAR CT-P13 [O] . B. Fautrel, M. Assing, N. Mammar, 2021

机译：POS0592 BioSimilar Infliximab疗法在类风湿性关节炎，强直性脊柱炎和银屑病关节炎：对富生素-Naïve患者的长期随访研究和从发起者转换为生物邮件CT-P13的患者

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab

著录项

引文网络

相似文献

相关主题

期刊订阅